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Abstract
There is increasing evidence that the microcirculation plays an important role in the pathogenesis of cardiovascular
diseases. Changes in retinal vascular caliber reflect early microvascular disease and predict incident cardiovascular events.
We performed a genome-wide association study to identify genetic variants associated with retinal vascular caliber. We
analyzed data from four population-based discovery cohorts with 15,358 unrelated Caucasian individuals, who are members
of the Cohort for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, and replicated findings in four
independent Caucasian cohorts (n = 6,652). All participants had retinal photography and retinal arteriolar and venular caliber
measured from computer software. In the discovery cohorts, 179 single nucleotide polymorphisms (SNP) spread across five
loci were significantly associated (p,5.061028) with retinal venular caliber, but none showed association with arteriolar
caliber. Collectively, these five loci explain 1.0%–3.2% of the variation in retinal venular caliber. Four out of these five loci
were confirmed in independent replication samples. In the combined analyses, the top SNPs at each locus were: rs2287921
(19q13; p = 1.61610225, within the RASIP1 locus), rs225717 (6q24; p = 1.25610216, adjacent to the VTA1 and NMBR loci),
rs10774625 (12q24; p = 2.15610213, in the region of ATXN2,SH2B3 and PTPN11 loci), and rs17421627 (5q14; p = 7.32610216,
adjacent to the MEF2C locus). In two independent samples, locus 12q24 was also associated with coronary heart disease and
hypertension. Our population-based genome-wide association study demonstrates four novel loci associated with retinal
venular caliber, an endophenotype of the microcirculation associated with clinical cardiovascular disease. These data
provide further insights into the contribution and biological mechanisms of microcirculatory changes that underlie
cardiovascular disease.
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Introduction
Although both macrovascular and microvascular pathology are
associated with cardiovascular disease, including coronary artery
disease and stroke [1,2], most studies on the genetic determinants
of cardiovascular disease have primarily focused on macrovascular
disease traits, and genetic analyses of microvascular disease
phenotypes are rare [2,3]. This paucity of data is due to difficulties
in non-invasively assessing the microcirculation. However, retinal
arterioles and venules, which range between 50 to 300 mm in
diameter, can be directly imaged, and provide an ideal
opportunity to study the microcirculation in vivo [4].
Quantitative measurement of retinal blood vessel caliber from
photographs allows a non-invasive direct assessment of the human
microcirculation [4]. Studies using this technique have shown that
changes in retinal vascular caliber (e.g., narrower arteriolar and
wider venular caliber) are associated with a range of cardiovascular
diseases and their risk factors [5,6], including hypertension [7],
diabetes mellitus [8,9], stroke [10], coronary heart disease [11], and
cerebral small vessel disease [12,13]. Retinal vascular caliber is also
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an early marker of major eye diseases such as diabetic retinopathy
and age-related macular degeneration [14–16].
Recent studies suggest that genetic factors may play a role in
influencing retinal vascular caliber [17–20], so understanding
specific genetic factors underlying retinal vascular caliber could
therefore demonstrate novel insights into the mechanisms that
contribute to the microvascular pathways of cardiovascular and
eye diseases. To identify the underlying genetic determinants of
retinal arteriolar and venular caliber, we meta-analyzed results of
genome-wide association studies (GWAS) of 15,358 white
participants from four large, prospective population-based cohorts
included in the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) consortium [21]: the Age
Gene/Environment Susceptibility – Reykjavik Study (AGES) [22],
the Atherosclerosis Risk in Communities Study (ARIC) [23], the
Cardiovascular Health Study (CHS) [24] and the Rotterdam
Study [25]. We replicated our findings in four independent cohorts
of Caucasian ethnicity [the Australian Twins Study [26], the UK
Twins Study [27], the Beaver Dam Eye Study (BDES) [11], and
the Blue Mountains Eye Study (BMES)] [11]. Finally, in order to
examine the association between the replicated hits and cardio-
vascular diseases, we used data on coronary artery disease from the
Wellcome Trust Case Control Consortium (WTCCC) [3], on
stroke and myocardial infarction from the Heart and Vascular
Health (HVH) Study [28,29], on hypertension from the Global
Blood Pressure Genetics (Global BPgen) Consortium [30], and on
diabetes mellitus from the Diabetes Genetics Replication and
Meta-analysis + (DIAGRAM+) Consortium [31].
Results
Study samples
The total study sample for the discovery analyses was 15,358
and for the replication analyses 6,652. Characteristics of both the
discovery and replication samples are presented in Table 1.
Author Summary
The microcirculation plays an important role in the
development of cardiovascular diseases. Retinal vascular
caliber changes reflect early microvascular disease and
predict incident cardiovascular events. In order to identify
genetic variants associated with retinal vascular caliber, we
performed a genome-wide association study and analyzed
data from four population-based discovery cohorts with
15,358 unrelated Caucasian individuals, who are members
of the Cohort for Heart and Aging Research in Genomic
Epidemiology (CHARGE) consortium, and replicated find-
ings in four independent Caucasian cohorts (n = 6,652). We
found evidence for association of four loci with retinal
venular caliber: on chromosomes 19q13 within the RASIP1
locus, 6q24 adjacent to the VTA1 and NMBR loci, 12q24 in
the region of ATXN2,SH2B3 and PTPN11 loci, and 5q14
adjacent to the MEF2C locus. In two independent samples,
locus 12q24 was also associated with coronary heart
disease and hypertension. In the present study, we
demonstrate that four novel loci were associated with
retinal venular caliber, an endophenotype of the microcir-
culation associated with clinical cardiovascular disease. Our
findings will help focus research on novel genes and
pathways involving the microcirculation and its role in the
development of cardiovascular disease.
Table 1. Baseline characteristics of both the discovery and replication cohorts.
Discovery cohorts Replication cohorts
AGES ARIC CHS RS
Australian
Twins UK Twins BDES BMES
Original cohort 5,764 15,792 5,888 7,983 2,235 8,810 2,579 3,508
Non-Hispanic whites in original cohort 11,478 4,925 7,983 2,190 8,810 2,579 3,487
Total number included in analyses 2,949 6,317 1,272 4,820 1,709 1,132 2,522 1,310
Mean age (years) (SD) [range] 76.2 (5.4)
[66–94]
60.3 (5.6)
[50–72]
78.4 (4.1)
[72–95]
68.0 (8.2)
[55–99]
22.5 (12.4)
[5–90]
58.1 (10.1)
[16–81]
60.6 (10.8)
[43–86]
66.0 (8.6)
[49–93]
Proportion female (%) 57.5 52.9 62.9 59.0 57.0 97.7 55.8 58.4
Mean CRAE (mm) (SD) [range] 139.7(13.4)
[74.0–221.4]
136.1 (14.3)
[72.6–203.8]
140.4 (15.7)
[77.6–197.4]
150.0 (14.4)
[98.5–235.4]
164.2 (13.6)
[83.6–205.2]
163.8 (18.1)
[91.0–219.6]
149.5 (13.7)
[100.3–196.6]
160.0 (20.2)
[93.4–213.4]
Mean CRVE (mm) (SD) [range] 202.0(19.5)
[123.8–273.0]
199.4 (19.2)
[129.3–304.1]
196.5 (19.2)
[142.5–271.7]
226.0 (20.1)
[162.5–324.3]
248.0 (19.0)
[130.5–325.7]
253.0 (28.6)
[147.0–338.0]
230.3 (21.7)
[165.9–335.1]
238.4 (24.0)
[167.6–331.1]
Systolic blood pressure (mm Hg) (SD)
[range]
142.5(20.2)
[92–253]
122.9 (18.1)
[75–226]
134.4 (20.4)
[82–241]
138.5 (22.1)
[74–250]
N/A 130.5 (19.7)
[85–210]
130.5 (20.0)
[71–248]
146.0 (20.5)
[95–240]
Diastolic blood pressure (mm Hg) (SD)
[range]
74.1 (20.2)
[92–253]
70.8 (10.0)
[32–114]
67.9 (10.8)
[15–110]
73.7 (11.4)
[24–139]
N/A 79.5 (11.9)
[50–124]
77.4 (10.8)
[44–123]
83.6 (9.8)
[50–125]
Hypertension (%) 80.6 35.3 48.7 42.3 3.2 41.7 35.1 46.1
Diabetes mellitus (%) 11.4 12.4 12.2 10.0 1.0 1.5 10.3 7.9
Current smokers (%) 12.5 17.3 6.2 23.6 11.0 13.8 21.6 12.4
Body mass index (kg/m2) (SD) [range] 27.1 (4.4)
[14.8–48.5]
28.0 (5.2)
[14.2–59.1]
26.8 (4.3)
[15.6–46.7]
26.3 (3.7)
[14.2–50.7]
N/A 25.6 (4.3)
[15.0–48.2]
28.3 (5.2)
[15–55]
26.3 (4.4)
15.2–49.2
AGES: Age Gene/Environment Susceptibility – Reykjavik Study; ARIC: Atherosclerosis Risk in Communities Study; CHS: Cardiovascular Health Study; RS: Rotterdam Study;
BDES: Beaver Dam Eye Study; BMES: Blue Mountains Eye Study; CRAE: central retinal arteriolar equivalent; CRVE: central retinal venular equivalent; SD: standard
deviation; N/A Not available.
doi:10.1371/journal.pgen.1001184.t001
Four Novel Loci Influence the Microcirculation
PLoS Genetics | www.plosgenetics.org 3 October 2010 | Volume 6 | Issue 10 | e1001184
Meta-analysis of CHARGE cohort results
A total of 179 single nucleotide polymorphisms (SNPs) at five loci
surpassed our preset threshold (p,5.061028) for genome-wide
significance for retinal venular caliber. Collectively, these five
independent loci explain 1.0–3.2% of the variation in retinal
venular caliber within our discovery cohorts. The QQ-plots (Figure
S1A) show departure from the line of identity at approximately
p,1.061023. Figure 1A displays the minus log-transformed p-
values for the individual SNPs against their genomic position.
Table 2 summarizes both the meta-analyzed results and results from
each discovery cohort individually for the most significant SNPs at
each locus that were associated with retinal venular caliber.
No genome-wide significant locus was identified for retinal
arteriolar caliber and only one SNP was associated with retinal
arteriolar caliber at a significance threshold between 5.061028
and 1.061026. The QQ-plot (Figure S1B) showed a departure
from the line of identity at approximately p,1.061024. Figure 1B
displays the minus log-transformed p-values for the individual
SNPs against their genomic position. The most significant signal
was on chromosome 13q12 (rs2281827, per minor allele (T) copy
1.0 mm (SE: 0.21) increase in arteriolar caliber; minor allele
frequency (MAF): 0.23; p = 3.5361027). This signal on chromo-
some 13q12 was located in FLT1, also known as vascular
endothelial growth factor receptor.
Replication in independent cohorts
Table 3 shows the results within each replication cohort for the
five loci that were genome-wide significant in the discovery phase.
Minor allele frequencies in the replication cohorts were very
similar to that in the discovery cohorts. Four out of the five loci
showed consistent effects in the combined analyses of the
replication cohorts at a Bonferroni-corrected significance thresh-
old of p,0.01 (0.05/5, as five loci were tested in the replication
phase), the exception was rs7824557 (8p23). The combined
analyses of the discovery and replication cohorts yielded an
overall p-value of 1.61610225 for rs2287921 (19q13). The
corresponding values for the other loci were p = 1.25610216 for
rs225717 (6q24), p = 2.15610213 for rs10774625 (12q24) and
p = 7.32610216 for rs17421627 (5q14). Finally, for rs7824557
(8p23) the overall p-value did not reach genome-wide significance
(p = 3.8061027).
The regional association plots for these four loci are presented in
Figure 2A–2D. After additional adjustments for hypertension and
diabetes mellitus, the associations between the four replicated loci
and retinal venular caliber remained the same (Table S1).
Associations with cardiovascular diseases
Table 4 presents the results with clinical cardiovascular diseases
for the four loci that were successfully replicated in the replication
cohorts. These association results provided evidence for 12q24 as a
risk locus for coronary artery disease and hypertension. The allelic
odds ratios of rs10774625 were 1.13 (95% confidence interval (CI):
1.03–1.24; p = 0.008) for coronary artery disease and 1.06 (95%
CI: 1.01–1.12; p = 0.019) for hypertension. As we found the most
convincing evidence for rs10774625 to be associated with
coronary artery disease, we examined the association with
coronary artery disease for all 10 SNPs on locus 12q24 that were
genome-wide significant in the current analysis with retinal
venular caliber. Figure 3 shows a plot in which the p-values for
these 10 SNPs from the current analysis are combined with those
for coronary artery disease from WTCCC. We found that all 10
SNPs were significantly associated with coronary artery disease at
a nominal p-value of 0.05 suggesting a strong overlap between the
association signals of retinal venular caliber and coronary artery
disease.
Discussion
In this meta-analysis of GWAS data from four populations on
retinal microcirculation and subsequent replication in four
independent cohorts, we identified four novel loci on chromo-
somes 19q13, 6q24, 12q24 and 5q14 that were consistently
associated with retinal venular caliber in persons of Caucasian
descent at genome-wide significance of ,5.061028. The most
significant SNPs at each of the four loci were associated with an
approximate 2.0mm change in retinal venular caliber for each copy
of the minor allele. Locus 12q24 was also associated with coronary
heart disease and hypertension. We did not find any loci that
reached genome-wide significance for retinal arteriolar caliber,
and only one SNP reached highly suggestive levels.
Our study is the first large study to evaluate common genetic
variants of the microcirculation, increasingly thought to play a
substantial role in the pathogenesis and development of clinical
cardiovascular diseases, including coronary heart disease and
stroke. The retinal vasculature provides a non-invasive direct view
of the human microcirculation. Retinal venular caliber has been
shown to predict a range of subclinical [5] and clinical
cardiovascular disease [6]. In a recent meta-analysis, wider retinal
venules were associated with a hazard ratio of 1.16 (95% CI: 1.06–
1.26) for coronary artery disease in women while controlling for
other known cardiovascular risk factors [11]. Furthermore, wider
venular caliber predicted risk of stroke and is associated with
progression of cerebral white matter lesions [10,12]. Both systemic
and environmental factors likely induce variation in retinal venular
caliber along with individual genetic differences [5,6,17–20].
Wider retinal venular caliber has been hypothesized to reflect the
effects of hypoxia [32], and an increased nitric oxide production
and release of cytokines resulting from activated endothelial cells
Figure 1. P-values (minus log-transformed) are shown in a signal intensity (Manhattan) plot relative to their genomic position. For
(a) retinal venular caliber and (b) retinal arteriolar caliber.
doi:10.1371/journal.pgen.1001184.g001
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[33]. This is supported by clinical and epidemiological studies
showing larger venular caliber to be associated with systemic
biomarkers of inflammation, including C-reactive protein and
interleukin-6, and with impaired fasting glucose metabolism,
dyslipidemia, obesity and cigarette smoking [5,34].
The most significant SNP associated with retinal venular caliber
was in the RASIP1 gene (rs2287921, p = 1.61610225) on
chromosome 19q13. RASIP1 belongs to the family of RAS
molecules, which have recently been implicated in animal models
to be involved in vascular development, endothelial cell migration,
capillary tube assembly, blood vessel homeostasis and vascular
permeability [35]. Specifically, RASIP1 is expressed in the
endothelium of the developing blood vessels and is essential for
proper endothelial cell angiogenic assembly and migration [35].
On chromosome 6q24, the top SNPs were located in or
adjacent to VTA1 and NMBR genes. VTA1 encodes a protein
involved in trafficking of the multivesicular body, an endosomal
compartment involved in sorting membrane proteins for degra-
dation in lysosomes [36]. Neuromedin B (NMB) is a peptide that
acts by binding to a specific receptor protein (NMBR) and is
involved in a number of physiological processes including immune
defense, thyroid, adrenocortical function and cognition. NMB is
also aberrantly expressed by a variety of cancers and is involved in
tumor cell proliferation [37].
The signals for association on chromosome 12q24 were spread
across a large 1 Mb LD block, including genes such as SH2B3,
ATXN2 and PTPN11. The most significant SNP was located in
ATXN2. Defects in the ATXN2 are the cause of spinocerebellar
ataxia type 2 (SCA 2), which belongs to the autosomal cerebellar
ataxias characterized by cerebellar ataxia, optic atrophy, ophthal-
moplegia and dementia. SCA 2 is caused by extension of a CAG
repeat in the coding region of this gene. Another gene in this
region is SH2B3, which is expressed by vascular endothelial cells
and regulates growth factor and cytokine receptor-mediated
pathways implicated in lymphoid, myeloid and platelet homeo-
stasis [38]. Our study showed that the most significant SNP in the
SH2B3 region was rs3184504 (p = 4.88610211). Interestingly, this
variant is associated with type 1 diabetes mellitus, a disease in
which the risk of developing complications was found to be
associated with wider retinal venular caliber [38]. Recent GWAS
studies have shown that several SNPs at the locus 12q24 (e.g.
rs11065987 in ATXN2 and rs11066301 in PTPN11) are associated
with platelet count, hemoglobin concentration, hematocrit, and
blood pressure [39–41]. Furthermore, replication in independent
case-control series including 9,479 cases and 10,527 controls have
shown odds ratios of 1.14 (95% CI: 1.10–1.20; p = 2.5261029)
and 1.15 (95% CI: 1.10–1.20; p = 7.05610211) per minor allele
copy for the association of these two SNPs with coronary artery
disease [39]. The corresponding allelic odds ratios for myocardial
infarction were 1.17 (95% CI: 1.11–1.22; p = 3.43610210) and
1.18 (95% CI: 1.12–1.23; p = 2.42610212) [39]. In our discovery
cohort, apart from rs10774625 we found nine additional SNPs in
the region that were genome-wide significant, including both
rs11065987 and rs11066301 (1.5 increase in venular caliber per
minor allele for both) that have also been shown to be associated
with coronary heart disease and myocardial infarction. Finally, in
the present study the association results from WTCCC and Global
BPgen confirmed locus 12q24 to be a risk locus for both coronary
artery disease and hypertension. Specifically, we found a strong
overlap between the association signals of retinal venular caliber
and coronay artery disease.
The most significant SNPs at the 5q14 locus were located in an
intergenic region. The closest gene in this region is MEF2C, which
is located about 200 kb downstream. Myocyte enhancer factor 2
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(MEF2) family proteins are key transcription factors, consisting of
four members MEF2A, MEF2B, MEF2C and MEF2D, controlling
gene expression in myocytes, lymphocytes, and neurons. MEF2
also plays an important role in cardiogenesis, epithelial cell
survival and maintenance of blood vessel integrity. Knockout of
MEF2C gene in mice is embryologically lethal due to failure in
cardiac development [42].
We did not find any loci that reached genome-wide significance
for retinal arteriolar caliber. It is possible that genetic factors play a
smaller role in arteriolar caliber, which is strongly associated with
increasing age and blood pressure [5–8]. It is also possible that
multiple genetic loci determine retinal arteriolar caliber and each
locus exerts only a very weak association that is not detectable
using our current study sample size. Thus, in order to examine
Figure 2. Regional association plots for the four novel loci. (a) Chromosome 19q13, (b) chromosome 6q24, (c) chromosome 12q24, and (d)
chromosome 5q14. The blue diamonds show stage 1 p-values (discovery phase) for the top SNP at each locus, whereas the grey diamonds show the
p-values following stage 2 meta-analysis including the replication cohorts for that top SNP. P-values from stage 1 for additional SNPs at each locus are
colour-coded according to their linkage disequilibrium with the top SNP as follows: r2,0.2 white, 0.2,r2,0.5 yellow, 0.5,r2,orange-red, r2.0.8 red.
doi:10.1371/journal.pgen.1001184.g002
Table 4. The association between the four novel loci and cardiovascular diseases.
CHARGE
(CRVE)
WTCCC
(CAD)
HVH
(stroke)
HVH
(MI)
Global BPgen
(HTN)
DIAGRAM+
(DM)
12q24
(rs10774625)
M.A.: A
Beta: 1.6
(SE 0.23)
P = 1.16610211
OR: 1.13
(1.03; 1.24)
P =0.008
OR: 1.03
(0.89; 1.20)
P = 0.66
OR: 1.05
(0.94; 1.18)
P = 0.39
OR: 1.06
(1.01; 1.12)
P =0.019
OR: 1.02
(0.98; 1.06)
P = 0.36
19q13 (rs2287921)
M.A.: T
Beta: 22.0
(SE 0.23)
P = 3.30610218
OR: 0.95
(0.87; 1.05)
P = 0.303
OR: 0.90
(0.77; 1.06)
P = 0.20
OR: 0.91
(0.81; 1.03)
P = 0.13
OR: 1.01
(0.96; 1.07)
P = 0.67
OR: 1.01
(0.97; 1.05)
P = 0.72
6q24
(rs225717)
M.A.: C
Beta: 21.8
(SE 0.27)
P = 5.99610212
OR: 0.98
(0.89; 1.08)
P = 0.65
OR: 1.11
(0.93; 1.32)
P = 0.24
OR: 1.12
(0.98; 1.27)
P = 0.11
OR: 0.98
(0.93; 1.04)
P = 0.55
OR: 0.98
(0.93; 1.02)
P = 0.33
5q14
(rs17421627)
M.A.: G
Beta: 2.5
(SE 0.43)
P = 5.0561029
OR: 1.02
(0.88; 1.18)
P = 0.81
OR: 1.15
(0.83; 1.59)
P = 0.39
OR: 1.02
(0.79; 1.31)
P = 0.89
OR: 1.07
(0.98; 1.17)
P = 0.14
OR: 0.98
(0.91; 1.05)
P = 0.60
CHARGE: Cohort for Heart and Aging Research in Genomic Epidemiology Consortium CRVE: central retinal venular equivalent (CRVE), SE: standard error; WTCCC:
Wellcome Trust Case Control Consortium; CAD: coronary artery disease; HVH: Heart and Vascular Health Study; MI: myocardial infarction; Global BPgen: Global Blood
Pressure Genetics Consortium; HTN: hypertension; DIAGRAM+: Diabetes Genetics Replication and Meta-analysis+; DM: diabetes mellitus; M.A.: Minor allele within
CHARGE; OR: odds ratio (with corresponding 95% confidence interval) per copy of the minor allele.
doi:10.1371/journal.pgen.1001184.t004
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genetic associations with retinal arteriolar caliber more fully, we
are currently in the process of building collaborations with several
other studies to increase the sample size of the discovery cohort.
While we have identified four loci associated with retinal
venular caliber, the identified SNPs may not represent the causal
variants but could be in high linkage disequilibrium (LD) with the
causal variants, which remain to be discovered. Further fine
mapping of this genomic region will be required to facilitate
expression and translational studies. Our study suggests that the
effect of common genetic variants on retinal vascular caliber is
small, and explain only a small proportion of the heritability of
these traits [43]. It remains possible that low frequency variants
might be important, but GWAS provides poor coverage of rare
variants. With the study populations of predominantly Caucasian
descent and stringent checks for latent population substructure, the
associations are unlikely to be due to population stratification.
To conclude, our population-based GWAS demonstrate four
novel loci on chromosomes 19q13 (within the RASIP1 locus), 6q24
(adjacent to the VTA1 and NMBR loci), 12q24 (in the region of the
SH2B3, ATXN2 and PTPN11 loci) and 5q14 (adjacent to the MEF2C
locus) associated with retinal venular caliber, an endophenotype of
the microcirculation associated with clinical cardiovascular disease.
Furthermore, locus 12q24 was also associated with coronary heart
disease and hypertension. While further studies are needed to
determine the causal genetic variants that underlie the heritability of
this endophenotype, our findings will help focus research on novel
genes and pathways involving the microvasculature and its role in the
pathogenesis and development of cardiovascular disease.
Materials and Methods
Ethics statement
Each cohort secured approval from their respective institutional
review boards, and all participants provided written informed
consent in accordance with the Declaration of Helsinki.
Consortium organization
The CHARGE consortium included large prospective commu-
nity-based cohort studies that have genome-wide marker data and
extensive data on multiple phenotypes [21]. All participating
Figure 3. A combined regional association plot showing p-values from CHARGE for the 10 SNPs on 12q24 for retinal venular caliber
and from WTCCC for coronary artery disease.
doi:10.1371/journal.pgen.1001184.g003
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studies approved guidelines for collaboration, and a working group
arrived at a consensus on phenotype harmonization, covariate
selection and analytic plans for within-study analyses and meta-
analyses of results.
Setting
Details of cohort selection, risk factor assessment and retinal
vascular caliber measurements in the four studies have been
described in Text S1, section 1 [11,22–25]. The AGES is a
prospective study with subject recruitment from 2002–2006 of
5,764 surviving members, aged 66 years and older, of the
established Reykjavik Study, a cohort of 19,381 participants
assembled in 1967 to study cardiovascular disease and its risk
factors among those born between 1907 and 1935 [22]. The ARIC
study enrolled 15,792 men and women (including 11,478 non-
Hispanic whites) from four U.S. communities to investigate the
etiology and sequelae of atherosclerosis and cardiovascular risk
factors [23]. Participants were between age 45 and 64 years at their
baseline examination in 1987–1989. The CHS enrolled 5,888
adults 65 years and older from four field centers to study coronary
artery disease and stroke. The baseline examination took place
either in 1989–90 or 1992–93 [24]. The Rotterdam Study enrolled
7,983 inhabitants from a district of Rotterdam aged 55 years and
older to study cardiovascular, neurological, ophthalmic and
endocrine diseases. The baseline examination was in 1990–93 [25].
Study population
The AGES and Rotterdam cohorts consisted predominantly of
Caucasian whites. Only non-Hispanic white participants were
included from the ARIC and CHS. Retinal photographs were
obtained from participants at the third examination in ARIC and
the tenth in CHS. Participants were excluded if their photographs
could not be graded (due to cataract, corneal opacities or poor
focus) or if genotyping data were unavailable (Table 1).
Retinal vascular caliber measurements
Retinal vascular caliber was measured using standardized
protocols and software that were developed initially at the
University of Wisconsin and used in the ARIC study and the
CHS, and following slight modifications, also in the Rotterdam
and AGES studies (Text S1, section 2) [4,5,9,11,13]. In brief,
participants underwent retinal photography and optic disc-
centered images were used to measure vascular caliber. Pharma-
cological mydriasis was used in the AGES and Rotterdam studies.
For ARIC, CHS and Rotterdam the photographs of one eye were
digitized using a high-resolution scanner and for the AGES study,
photographs of both eyes were captured digitally. All digital retinal
images were analyzed with a semi-automated retinal vessel
measurement system and the calibers of all retinal arterioles and
venules were measured in an area between half and one disc-
diameter from the optic disc margin. The Parr-Hubbard-
Knudtson formulae were used to compute summary measures
for retinal arteriolar and venular calibers in micrometers (mm) and
referred to as the ‘‘central retinal arteriolar and venular
equivalents’’ [44]. Quality control (QC) measures for intergrader
and intragrader intraclass correlation coefficients for retinal
vascular calibers for each of the cohorts ranged from 0.76–0.99
in AGES, 0.69–0.89 in ARIC, 0.67–0.91 in CHS to 0.67–0.95 in
the Rotterdam Study [4,5,9,13].
Genotyping
The consortium was formed after the individual studies had
finalized their GWAS platform selection. The four studies
included used different platforms: the Affymetrix GeneChip SNP
Array 6.0 for the ARIC study, Illumina HumanCNV370-Duo for
the AGES study and the CHS and the Illumina Infinium
HumanHap550-chip v3.0 for the Rotterdam Study. All studies
used their genotype data to impute to the 2.2 million non-
monomorphic, autosomal, SNPs identified in HapMap (CEU
population). Extensive QC analyses were performed in each
cohort (Text S1, sections 3 and 4) [21].
Statistical analyses within discovery cohorts
Based on an a priori analysis plan, each study fitted an additive
genetic model with a 1-degree of freedom trend test relating the
retinal arteriolar or venular caliber to genotype dosage (0–2 copies
of the minor allele) for each SNP, adjusting for age and sex. For
the CHS and ARIC studies, the analyses were additionally
adjusted for study site. We used linear regression models to
calculate regression coefficients (beta) and their standard errors
(SE) using the ProbABEL program (http://mga.bionet.nsc.ru/
,yurii/ABEL/) in AGES, ARIC and Rotterdam study and the R
software in CHS (http://www.r-project.org). Genomic control
correction was applied in each study prior to the meta-analysis. To
implement genomic control, the lgc value was used to correct the
SE as follows: SE_corrected = SE6!lgc. All four cohorts showed
low dispersion with inflation factors in the range of 1.030–1.071.
Meta-analysis
We conducted a meta-analysis of the beta estimates obtained
from the linear regression models from the four cohorts using an
inverse-variance weighting using the R software (MetABEL) (Text
S1, section 5) [45]. Strand information was available from all
cohorts, facilitating the meta-analysis. After QC, filtering, and
imputation within each study, we restricted our meta-analysis to
the 2,194,468 autosomal SNPs that were common to all cohorts.
We decided a priori on a genome-wide significance threshold of
p,5.061028 which corresponds to a p-value of 0.05 with
Bonferroni correction for one million independent tests. For 2.2
million tests, it corresponds to an expectation of only 0.11 false
positives, regardless of test-dependence [46]. Use of this threshold
is also supported by LD patterns observed in deep sequencing
work within European populations [47].
Replication analyses
The genome-wide significant SNPs for each locus from the
discovery phase were examined in four replication cohorts. The
four replication sample sets included 1,709 participants from the
Australian Twins Study, 1,132 from the UK Twins Study, 2,501
from the BDES and 1,310 from the BMES. Retinal vascular
caliber measurements used the same methodology and formulas as
in the CHARGE cohorts. Details of this and the procedures for
genotyping are described in the Text S1, sections 1 and 2. In brief,
in the Australian Twins Study, genotyping was performed on the
Illumina Human Hap610W Quad array. In the UK Twins Study,
56% of the participants were genotyped using the Illumina 317k
HumanHap duo array, whereas the remaining 44% using the
Illumina HumanHap610Quad array. In the BDES, SNPs were
genotyped using TaqMan SNP genotyping assays (Applied
Biosystems, CA). Finally, in the BMES genotyping was performed
using the Illumina 610K array.
Analyses with cardiovascular diseases
In order to examine the association between SNPs that were
successfully replicated in the current study and cardiovascular
diseases, we obtained association statistics for each of these SNPs
Four Novel Loci Influence the Microcirculation
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from several GWA studies. We obtained these data from the
WTCCC on 2000 cases with coronary artery disease and 3000
controls [3], from HVH Study on 501 cases with stroke [28], 1,172
cases with myocardial infarction and 1,314 controls [29], from
Global BPgen on 8,871 cases with hypertension and 9,027 controls
[30], and from DIAGRAM+ on 8,130 cases with diabetes mellitus
and 38,987 controls [31]. Details of each these studies have been
described in the Text S1, section 6.
Supporting Information
Figure S1 Quantile-quantile (QQ)-plot showing the minus log-
transformed observed versus the expected p-values after meta-
analysis for (A) retinal venular and (B) arteriolar caliber.
Found at: doi:10.1371/journal.pgen.1001184.s001 (0.26 MB TIF)
Table S1 The association between the top SNPs per genome-
wide significant locus and retinal vascular caliber additionally
adjusted for diabetes mellitus and hypertension.
Found at: doi:10.1371/journal.pgen.1001184.s002 (0.05 MB
DOC)
Text S1 Sample selection, retinal vascular caliber measure-
ments, genotyping quality control filters and imputation, screening
for latent population substructure, meta-analysis techniques,
analyses with cardiovascular diseases, reference list.
Found at: doi:10.1371/journal.pgen.1001184.s003 (0.09 MB
DOC)
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